Population Pharmacokinetic and Pharmacodynamic Analysis of GLPG1690, an Autotaxin Inhibitor, in Healthy Volunteers and Patients with Idiopathic Pulmonary Fibrosis

por Taneja, Amit, Desrivot, Julie, Diderichsen, Paul Matthias, Blanqué, Roland, Allamasey, Lisa, Fagard, Liesbeth, Fieuw, Ann, Van der Aar, Ellen, Namour, Florence
Publicado 2019

Safety, Pharmacokinetics, and Pharmacodynamics of the Autotaxin Inhibitor GLPG1690 in Healthy Subjects: Phase 1 Randomized Trials

por van der Aar, Ellen, Desrivot, Julie, Dupont, Sonia, Heckmann, Bertrand, Fieuw, Ann, Stutvoet, Simone, Fagard, Liesbeth, Van de Wal, Karen, Helmer, Eric
Publicado 2019

Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and...

por Maher, Toby M, Kreuter, Michael, Lederer, David J, Brown, Kevin K, Wuyts, Wim, Verbruggen, Nadia, Stutvoet, Simone, Fieuw, Ann, Ford, Paul, Abi-Saab, Walid, Wijsenbeek, Marlies
Publicado 2019

Safety, Pharmacokinetics, and Pharmacodynamics of the ADAMTS‐5 Inhibitor GLPG1972/S201086 in Healthy Volunteers and Participants With Osteoarthritis of the Knee or Hip

por van der Aar, Ellen, Deckx, Henri, Dupont, Sonia, Fieuw, Ann, Delage, Stephane, Larsson, Staffan, Struglics, André, Lohmander, L. Stefan, Lalande, Agnes, Leroux, Emilie, Amantini, David, Passier, Paul
Publicado 2021